

Case Report

DOI: 10.4274/jcrpe.galenos.2025.2024-10-16

Four Consecutive False Negative Newborn Screens in a Patient with Classical Congenital Adrenal Hyperplasia: A Case Report

Rizzuto P et al. Consecutive False Negative Newborn Screens in CAH

Patrick Rizzuto, Mariam Gangat, Ahmed Khattab, Ian Marshall
Rutgers Robert Wood Johnson Medical School, Division of Pediatric Endocrinology, New Jersey, United States

What is already known on this topic?

Classical congenital adrenal hyperplasia (CAH) presents early in life and requires lifelong treatment. It is marked by life-threatening “adrenal crises” due to critical steroid hormone deficiency. Newborn screening (NBS) offers protection against such crises by allowing diagnosis and treatment of CAH soon after birth, when patients are still generally asymptomatic. It is imperative that NBS has high sensitivity to minimize false negatives.

What this study adds?

NBS for CAH, including classical CAH, is subject to false negative results, even using high-sensitivity assays. Possible sources of false negative results on NBS for CAH include antenatal steroids, decreased 11HSD2 activity in pregnancies with IUGR, and sodium supplementation prior to sample collection. Persistent hyponatremia without an alternate explanation may indicate classical CAH in spite of normal NBS results.

Abstract

21-hydroxylase deficiency is the most common cause of congenital adrenal hyperplasia (CAH). Salt-wasting CAH can present with life-threatening salt-wasting crises, underscoring the importance of universal newborn screening. We present a patient diagnosed with classical CAH despite four negative newborn screen results (NBS) results. A male infant was born at 35 weeks gestation with birthweight 1470 grams following signs of placental insufficiency. While hospitalized in the neonatal intensive care unit (NICU), four NBS samples from days of life 2 to 38 were all within normal range, including on repeat analysis via fully integrated fluoroimmunoassay. After initially normal biochemical testing, hyponatremia and hyperkalemia developed by day of life (DOL) 26, responsive to sodium chloride supplementation. Following recurrent hyponatremia after trial off supplementation after day of life 50, 17-hydroxyprogesterone as measured via liquid chromatography-tandem mass spectrometry were reported at two different labs as 10,900 ng/dL and 11,200 ng/dL (<2 ng/dL at 50 DOL). Subsequent testing identified deletion of one *CYP21A2* allele and a *1172N* mutation in the second. This report illustrates the importance of maintaining a high index of suspicion for classic forms of CAH in infants with persistent electrolyte disturbances despite negative NBS results.

Keywords: Congenital adrenal hyperplasia; newborn screening; hyponatremia; 17-hydroxyprogesterone

Ian Marshall, MD, Rutgers Robert Wood Johnson Medical School, Division of Pediatric Endocrinology, New Jersey, United States
marshaia@rwjms.rutgers.edu
0000-0001-7778-4331

23.10.2024

03.04.2025

Epub: 09.03.2026

Introduction

Steroid 21-hydroxylase deficiency (21-OHD) is the most common cause of congenital adrenal hyperplasia (CAH), resulting from deficiency of the 21-hydroxylase enzyme encoded by *CYP21A2* that plays an essential role in cortisol and aldosterone synthesis in the adrenal cortex. The most common classic forms consist of simple virilizing (SV) type which accounts for 25% of classic 21-OHD; and the salt-wasting type (SW), which accounts for more than 75% of affected individuals (1).

In all 50 of the United States, including New Jersey, newborn screening obtained in the neonatal period includes 17-hydroxyprogesterone (17-OHP) to identify and begin treatment of CAH before the life-threatening salt-wasting crises that occur in SW CAH without hormone replacement are likely to develop. In New Jersey, state law requires this newborn screen to be obtained in all babies 24 to 48 hours after birth. 17-OHP is measured using the Revvity DELFIA assay. The thresholds for elevated values vary depending on birthweight, increasing with lower weight. These cutoffs are included in Table 1.

Given the high sensitivity of newborn screening, providers may prematurely conclude there is no possibility of CAH in babies with a negative screening result. However, false negative newborn screens for CAH have been reported in the literature. One identified risk factor for a false negative CAH screen is antenatal steroid administration, such as to induce fetal lung maturity. Even in the absence of antenatal steroids, the possibility remains of a false negative CAH screen. Given the life-threatening nature of a salt-wasting crisis, failure to investigate the possibility of CAH and to institute appropriate treatment carries high morbidity and mortality.

In this case report, we present a patient diagnosed with the classic form of 21-OHD CAH despite four negative newborn screening (NBS) results. We identify pertinent features of his presentation that may have led to the false negative screens, as well as aspects that ultimately assisted in making the diagnosis. The parents of the patient consented to the publication of this case report.

Case Presentation

A Caucasian male was born at an outside institution at 35 weeks gestation by cesarean section for non-reassuring fetal heart tracing and intrauterine growth restriction (IUGR) to a 35-year-old mother. At 30 weeks, the mother was hospitalized due to absent end diastolic flow on umbilical Doppler, consistent with placental insufficiency. To promote fetal lung maturity, standard doses of glucocorticoids (2 doses of betamethasone at 12 mg/dose 24 hours apart) were administered at 30 and at 33 weeks gestation.

Both birth weight (BW) of 1470 g and length of 40.5 cm were consistent with small for gestational age (SGA). The baby was not in distress at birth. Examination revealed bilaterally descended testes palpable in a normally developed scrotum, and a normal sized phallus. He was admitted to the neonatal intensive care unit (NICU) for monitoring due to prematurity and to gradually introduce enteral feeds.

Initial routine biochemical testing showed normal sodium and potassium levels for postnatal age. After day of life (DOL) 26, hyponatremia and hyperkalemia developed with sodium of 127 mEq/L (various reference ranges have been proposed) (2) and potassium of 6.2 mEq/L (Harriet Lane newborn range: 3.7-5.9 mEq/L). Hyponatremia persisted with a nadir of 124; peak potassium was 8.0 mEq/L. These lab values are displayed in Table 2. Additional testing did not reveal hypoglycemia or metabolic acidosis. There was no hypotension, tachycardia, or other clinical evidence of dehydration.

The NICU team attributed both electrolyte disturbances to prematurity and started sodium chloride supplementation at 4 mEq/kg/day on DOL 30. The hyponatremia resolved, leading to discontinuation of sodium supplementation. After the supplement was stopped, hyponatremia then recurred within 1 day, and again resolved with reintroduction of sodium supplementation. Due to incomplete records, it is unclear if additional specific treatment was provided for the hyperkalemia, which normalized during the first course of sodium supplementation and did not recur at any point. On DOL 39, with appropriate sodium and potassium levels for postnatal age and on full enteral feeds, he was discharged home on sodium supplementation of 3 mEq/kg/day. While in the NICU, neither Pediatric Endocrinology nor Nephrology were consulted.

Eleven days after discharge, he was admitted to our institution on DOL 50 for additional evaluation due to the pediatrician's concern about the prior electrolyte abnormalities. His examination was unchanged. His weight of 2.78 kg represented an average daily weight gain since birth of approximately 30g.

During admission, at our request, all 4 NBS samples for CAH drawn on DOL 2, 6, 13 and 38 were re-analyzed in duplicate by the New Jersey Department of Health via fully integrated fluoroimmunoassay (3) and again were within the normal range.

During this second admission, electrolytes were normal on sodium supplementation. Hyponatremia developed within 1 day after supplementation was discontinued; hyperkalemia did not develop. Additional diagnostic testing off sodium at that time included plasma renin activity (PRA) of 120 ng/mL/hr (normal for 0-2 yrs: 1.4-7.8 ng/mL/hr; Mayo Medical Laboratories, Rochester, MN), and an aldosterone level of 24 ng/dL (normal for 31 days-11 months of age: 6.5-86 ng/dL; Mayo Medical Laboratories, Rochester, MN). Sodium supplementation was restarted followed by normalization of sodium within 1 day.

21-OHD CAH was considered despite the negative screening. Serum 17-OHP measurements on DOL 51 off sodium supplementation for 1 day performed at both Mayo Medical Laboratories (Rochester, MN) and Esoterix Laboratory Services (Calabasas Hills, CA) by liquid chromatography-tandem mass spectrometry were reported at 10,900 ng/dL and 11,200 ng/dL (<2 ng/dL at 50 DOL), respectively. Repeat levels five days after sodium supplementation was restarted had decreased to 2,850 and 2,250 ng/dL, respectively. The above lab values from the second hospitalization are displayed in Table 3.

A diagnosis of SW CAH was then made based on the history of hyponatremia and 17-OHP levels > 10,000 ng/dL on 2 assays. Hydrocortisone (15 mg/m²/day) and fludrocortisone (0.1 mg/day) were then started with sodium supplementation at 3 mEq/kg/day. Subsequent genetic testing for 21-OHD CAH at Mayo Medical Laboratories (Rochester, MN) with full Sanger gene sequencing and multiple ligation-dependent probe amplification identified deletion of one *CYP21A2* allele and the *I172N* mutation in the second allele.

Discussion

NBS for CAH using 17-OHP measurements was first introduced to the USA in the late 1970's, and since then has been adopted by all 50 states, as well as 52 other countries. In healthy, unaffected newborns, physiological 17-OHP levels are elevated at birth and then decline over the next 2-3 weeks (4). In contrast, levels in classic CAH typically increase postnatally (5). The main purpose of screening is to identify newborns with classic CAH, particularly the salt wasting form in males, to avoid potential life-threatening salt wasting crises. It is also utilized to prevent incorrect sex assignment in virilized females with classic CAH.

Certain studies have shown that the sensitivity of the NBS for CAH is lower than expected. Sarafoglou et al. (6) reviewed 838,241 NBS results in Minnesota reported over a 12-year period, and identified that of 67 patients with classic CAH, 15 were missed on initial NBS (ten with SV CAH and five with SW CAH; six males, nine females). This was a false negative rate (FNR) of 22%. The diagnosis in five of the female patients was based on presentation of atypical genitalia at birth. Although three others also presented with atypical genitalia at birth, their diagnoses were delayed until as early as three months and up to six years of age. The remaining female patient had vaginoplasty six years prior to diagnosis. Despite these numbers, the authors suggested that the FNR was likely even higher due to the likelihood of undiagnosed patients with CAH, patients moving out of state, and/or infants that may have died with unidentified CAH (6).

A review by Varness et al. (7) of all NBS results in Wisconsin over a 12-year period identified eight patients diagnosed with classic CAH whose NBS results were negative. Overall sensitivity was 86%; although constrained by small numbers, sensitivity was further determined by sex to be 67% in females and 97% in males. The higher FNR for females could be partly explained by significantly lower 17-OHP levels reported in females on NBS (7). However, as most female patients with classic CAH are expected to be virilized, detection prior to reporting of the NBS result should occur, making the reduced sensitivity less problematic for female patients. However, even significantly virilized females have unfortunately been missed as atypical genitalia may not be noted on physical examination (6).

Schreiner et al. (8) reported that in a questionnaire-based study sent to 24 medical center members of the German Working Group of Pediatric Endocrinology, five out of 214 children with classical CAH were not detected by NBS, including two with salt-wasting.

Based on the reported FNR using single screen protocols and the rise in 17-OHP after birth in classic CAH, 13 states have instituted a two-screen protocol to improve sensitivity (3). Chan et al. (9) reported that 11 out of 39 (28%) cases of classic CAH in Colorado were detected by the second NBS at age 8-14 days of life. A five-year retrospective study by Held et al. (4) demonstrated that 6.5% of all SW CAH cases missed on the first screen were identified by the second screen. Similarly in Texas, 14% of classic CAH cases were detected on a second screen (10). This patient's genotype is typically associated with SV CAH (1), although as in this case can also result in the SW phenotype (11). Certain

studies (6, 10) have found that the majority of CAH cases missed by NBS are SV CAH, due to less dramatic elevations in 17-OHP. This is an important distinction, as the motivation for NBS hinges on rapid detection prior to life-threatening crises developing, which are unlikely in the milder defects associated with SV CAH. It is notable, however, that this patient had significant enough disease to develop hyponatremia and hyperkalemia, and may have been spared clinical dehydration primarily due to being in a NICU for other reasons. Furthermore, the final 17-OHP levels that were obtained prior to diagnosis were robustly elevated, and well into the range associated with classical CAH. Therefore, while the FNR is likely lower in the population of patients with SW CAH whose identification is the primary goal of newborn screening, our case does demonstrate a possibility of false negative screening in patients who may potentially suffer clinical complications as a consequence. A possible explanation for this patient's initial two negative NBS results could be antenatal administration of glucocorticoids to promote lung maturity. Gatelais et al. (12) demonstrated that multiple courses of antenatal glucocorticoids lowered 17-OHP levels in the newborns by about 30% compared to controls. The reason is transplacental transfer of glucocorticoids with suppression of fetal adrenal steroidogenesis. Inhaled and intranasal corticosteroids have also been reported to produce the same effect (13). However, this postnatal suppression is believed to last only about 1 week (14), so would not likely explain the negative third and fourth NBS results. Even though in this case repeat NBSs did not detect CAH after the suppression is expected to have faded, repeating the NBS for infants born following antenatal glucocorticoid exposure, or alternatively checking a serum 17-OHP level, 1-2 weeks after delivery will lead to detection of some cases missed on the first screen. Sodium supplementation could explain the 4th negative NBS result, and the decrease in 17-OHP during the patient's readmission. As 21-hydroxylase enzyme plays a role in the production of both cortisol and aldosterone in the adrenal cortex, mutations in the *CYP21A2* gene in the SV type are expected to also affect aldosterone synthesis. In SV CAH, this can lead to a relative state of hypovolemia, which in turn stimulates production of renin, angiotensin II, and possibly vasopressin (15). Angiotensin II can directly stimulate adrenal steroidogenesis independently of adrenocorticotropic hormone (ACTH), while vasopressin can increase pituitary ACTH secretion. As sodium supplementation corrects hypovolemia, angiotensin II and vasopressin production decreases, in turn reducing adrenal steroidogenesis and lowering 17-OHP levels. Therefore, if repeating the NBS or measuring 17-OHP directly, it is crucial to do so prior to sodium supplementation in babies with hyponatremia, or if supplements have already been started to discontinue them prior to further evaluation, as in this case. An additional factor could be decreased activity of placental 11-hydroxysteroid dehydrogenase type 2 (11HSD2) reported in pregnancies complicated by IUGR (16). 11HSD2 inactivates cortisol by conversion to cortisone (16), thus protecting the fetus from potentially harmful effects of endogenous maternal glucocorticoids. We hypothesize that decreased 11HSD2 activity increases maternal cortisol levels that cross the placenta and induce suppression of fetal adrenal steroidogenesis, including 17-OHP production. It is possible this contributed to the false negative in our particular case in a manner similar to the antenatal glucocorticoids. A significant limitation to this case report is the lack of complete records. Since hyperkalemia was noted with the initial hyponatremia, but not subsequent episodes of it, additional information regarding any treatment for the hyperkalemia itself would have been valuable. Once a diagnosis of CAH has been established, the standard of care is to provide mineralocorticoid replacement with fludrocortisone in addition to hydrocortisone and sodium supplementation (15), as our patient ultimately received after diagnosis. It is also unclear if there was any labwork, such as renin and aldosterone, during the first admission exploring an adrenal pathology for the electrolyte abnormalities. Additional insights into the treating team's evaluation of the electrolyte disturbances, and why they were ultimately attributed to prematurity, would have allowed a more comprehensive analysis of this case.

Conclusion

Despite efforts to improve the sensitivity of NBS for CAH, challenges persist, with potentially devastating consequences. This report emphasizes the importance of maintaining a high index of suspicion for classic forms of CAH in all newborns presenting with similar electrolyte disturbances despite negative NBS results.

Learning points

- NBS for CAH, including SW CAH, is subject to false negative results.
- Possible sources of false negative results on NBS for CAH include antenatal steroids, decreased 11HSD2 activity in pregnancies with IUGR, and sodium supplementation prior to sample collection.

What is new?

- Persistent hyponatremia without an alternate explanation may indicate SW CAH in spite of normal NBS results.

References

1. Saroj Nimkarn, Karen Lin-Su & Maria I New. 2011. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. *Pediatric Clinics of North America* 58(5). 1281-1300
2. Adrienne R. Bischoff, Christopher Tomlinson & Jaques Belik. 2016. Sodium Intake Requirements for Preterm Neonates: Review and Recommendations. *Journal of Pediatric Gastroenterology and Nutrition* 63(6). e123-e129.
3. Sari Edelman, Hiral Desai, Trey Pigg, Careema Yusuf & Jelili Ojodu. 2020. Landscape of Congenital Adrenal Hyperplasia Newborn Screening in the United States. *International Journal of Neonatal Screening* 6(3). 64.
4. Patrice K. Held, Stuart K. Shapira, Cynthia F. Hinton, Elizabeth Jones, W. Harry Hannon & Jelili Ojodu. 2015. Congenital adrenal hyperplasia cases identified by newborn screening in one- and two-screen states. *Molecular Genetics and Metabolism* 116(3). 133-138.
5. Perrin C. White. 2013. Optimizing newborn screening for congenital adrenal hyperplasia. *The Journal of Pediatrics* 163(1). 10-12.
6. Kyriakie Sarafoglou, Katie Banks, Jennifer Kylo, Siobhan Pittock & William Thomas. 2012. Cases of congenital adrenal hyperplasia missed by newborn screening in Minnesota. *Journal of the American Medical Association* 307(22). 2371-2374.
7. Todd S. Varness, David B. Allen & Gary L. Hoffman. 2005. Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls. *The Journal of Pediatrics* 147(4). 493-498.
8. Felix Schreiner, Christoph Brack, Kirsten Salzgeber, Walburga Vorhoff, Joachim Woelfle & Bettina Gohlke. 2008. False negative 17-hydroxyprogesterone screening in children with classical congenital adrenal hyperplasia. *European Journal of Pediatrics* 167(4). 479-481.
9. Christine L. Chan, Kim McFann, Laura Taylor, Daniel Wright, Philip S. Zietler & Jennifer M. Barker. 2013. Congenital adrenal hyperplasia and the second newborn screen. *The Journal of Pediatrics* 163(1). 109-113.

10. B. L. Therrell Jr, S. A. Berenbaum, V. Manter-Kapanke, J. Simmank, K. Korman, L. Prentice, J. Gonzalez & S. Gunn. 1998. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. *Pediatrics* 101(4 Pt 1). 583-590.
11. Maria New, Moolamanni Abraham, Brian Gonzalez, Miroslav Domic, Maryam Razzaghy-Azar, David Chitayat, Li Sun, Mone Zaidi, Robert Wilson, Tony Yuen. 2013. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. *Proceedings of the National Academy of Sciences of the United States of America*. 110(7). 2611-2616.
12. Frédérique Gatelais, Jacques Berthelot, Frédérique Beringue, Philippe Descamps, Dominique Bonneau, Jean-Marie Limal & Régis Coutant. 2004. Effect of single and multiple courses of prenatal corticosteroids on 17-hydroxyprogesterone levels: implication for neonatal screening of congenital adrenal hyperplasia. *Pediatric Research* 56(5). 701–705.
13. Muriel Houang, Thao Nguyen-Khoa, Thibaut Eguether, Bettina Ribault, Séverine Brabant, Michel Polak, Irène Netchine & Antonin Lamazière. 2022. Analysis of a pitfall in congenital adrenal hyperplasia newborn screening: evidence of maternal use of corticoids detected on dried blood spot. *Endocrine Connections* 11(6). e220101.
14. P. L. Ballard, P. D. Gluckman, G. C. Liggins, S. L. Kaplan & M. M. Grumbach. 1980. Steroid and growth hormone levels in premature infants after prenatal betamethasone therapy to prevent respiratory distress syndrome. *Pediatric Research* 14(2). 122–127.
15. P. C. White & P. W. Speiser. 2000. Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. *Endocrine Reviews* 21(3). 245-291.
16. Eero Kajantie, Leo Dunkel, Ursula Turpeinen, Ulf-Håkan Stenman, Peter J. Wood, Mika Nuutila & Sture Andersson. 2003. Placental 11 β -hydroxysteroid dehydrogenase-2 and fetal cortisol/cortisone shuttle in small preterm infants. *The Journal of Clinical Endocrinology and Metabolism* 88(1). 493–500.

Table 1: 17-hydroxyprogesterone (17-OHP) thresholds used for newborn screening in the state of New Jersey. As birthweight decreases, the thresholds for elevated values increase. Above table provided by the Newborn Screening Laboratory of the New Jersey Department of Health.

Birth Weight (grams)	Within Acceptable Limits (ng/mL)	Borderline Range (ng/mL)	Presumptive/Critical Range (ng/mL)
<1500	<100	100 -<145	≥ 145
1500 -<2500	<60	60 -<80	≥ 80
2500 -<3000	<40	40 -<48	≥ 48
≥ 3000	<35	35 -<55	≥ 55

Table 2: Laboratory values obtained during first hospitalization, with respective normal ranges for given age.

Studies	DOL 26	Between DOL 26 and DOL 30 (prior to sodium supplementation)
Sodium (mEq/L)	127 (various)	124 (various)
Potassium (mEq/L)	6.2 (3.7-5.9)	8.0 (3.7-5.9)

Table 3: Laboratory values obtained during second hospitalization, with respective normal range for given age.

Studies	DOL 51	DOL 56 (after beginning hydrocortisone)
Plasma renin activity (ng/mL/hr)	120 (1.4-7.8)	
Aldosterone (ng/dL)	24 (6.5-86)	
Mayo Medical Laboratories 17-hydroxyprogesterone (ng/dL)	10,900 (<2)	2,850 (<2)
Esoterix Laboratory Services 17-hydroxyprogesterone (ng/dL)	11,200 (<2)	2,250 (<2)